InstitutionMD Anderson
DepartmentRadiation Oncology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ganetespib radiosensitization for liver cancer therapy. Cancer Biology and Therapy. 17:457-466.
    2. Intensity-modulated radiation therapy for anal cancer. Oncology. 24.
    3. Automatic treatment planning implementation using a database of previously treated patients. Journal of Physics: Conference Series. 489.
    4. Changes to physician processing times in response to clinic congestion and patient punctuality. BMJ Open. 6.
    5. Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Practical Radiation Oncology. 2:77-85.
    6. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy. Journal of Gastrointestinal Oncology. 4:343-351.
    7. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics. 94:571-579.
    8. Computed tomography imaging assessment of postexternal beam radiation changes of the liver. Future Oncology. 12:2729-2739.
    9. ACR appropriateness criteria® resectable stomach cancer. ONCOLOGY (United States). 29.
    10. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemporary Clinical Trials. 50:143-149.
    11. Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer. American Journal of Clinical Oncology: Cancer Clinical Trials. 39:18-26.
    12. ACR appropriateness criteria® borderline and unresectable pancreas cancer. ONCOLOGY (United States). 30.
    13. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB. 18:236-246.
    14. Reliable detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing. Annals of Surgery. 263:153-161.
    15. Neoadjuvant chemoradiation followed by interstitial prostate brachytherapy for synchronous prostate and rectal cancer. Practical Radiation Oncology. 2.
    16. Advances of stereotactic body radiotherapy in pancreatic cancer. Chinese Journal of Cancer Research. 27:349-357.
    17. Preoperative endorectal brachytherapy in the treatment of locally advanced rectal cancer. Seminars in Colon and Rectal Surgery. 25:26-32.
    18. A Tale of Two Systems. American Journal of Medical Quality. 31:279-280.
    19. High-dose-rate intraoperative radiation therapy. Journal of Contemporary Brachytherapy. 6:99-105.
    20. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget. 6:36903-36910.
    21. Improving an electronic system for measuring PROs in routine oncology practice. Journal of Cancer Survivorship. 10:573-582.
    22. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Practical Radiation Oncology. 6:417-424.
    23. Carcinoma of the Pancreas. 1397-1415.e7.
    24. Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. Annals of Surgery.
    25. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer. Annals of Surgical Oncology. 22:2352-2358.
    26. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals of Surgery.
    27. Liver metastases from pancreatic adenocarcinoma. 95-109.
    28. Gastrointestinal stereotactic body radiation therapy requires detailed normal tissue planning to prevent long-term complications. Practical Radiation Oncology. 3:147-148.
    29. Appropriate customization of radiation therapy for stage II and III rectal cancer. Practical Radiation Oncology.
    30. Organizing a multidisciplinary clinic. Chinese Clinical Oncology. 3.
    31. Browser based platform in maintaining clinical activities-use of the ipads in head and neck clinics. Journal of Physics: Conference Series. 489.
    32. Stereotactic body radiotherapy for pancreatic cancer. Expert Review of Anticancer Therapy. 16:523-530.
    33. The tolerance of gastrointestinal organs to stereotactic body radiation therapy. Journal of Gastrointestinal Oncology. 5:236-246.
    34. Multidisciplinary care of patients with intrahepatic cholangiocarcinoma. Gastroenterology Research and Practice. 2015.
    35. Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer. Medical Physics. 43:5779-5790.
    36. Multidisciplinary management and the future of treatment in cholangiocarcinoma. Expert Opinion on Orphan Drugs. 4:255-267.
    37. Phosphorus-32, a clinically available drug, inhibits cancer growth by inducing DNA double-strand breakage. PLoS One. 10.
    38. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer alliance for clinical trials in oncology trial A021101. JAMA Surgery. 151.
    39. Foreword. Current Problems in Cancer. 37:258.
    40. ACR Appropriateness Criteria®-Anal Cancer. Gastrointestinal Cancer Research. 7:4-14.
    41. Adjuvant chemotherapy and radiation following PDD for pancreatic adenocarcinoma. American Journal of Hematology/ Oncology. 8.
    42. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB.
    43. Pancreatic cancer and FOLFIRINOX. Cancer Medicine. 4:853-863.
    44. Radiation Therapy for Colorectal Adenocarcinoma. 185-200.
    45. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discovery. 6:166-175.
    46. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. Journal of Gastrointestinal Oncology. 6:115-125.
    47. A practical framework for patient care teams to prospectively identify and mitigate clinical hazards. Joint Commission Journal on Quality and Patient Safety. 35:72-81.
    48. ACR appropriateness criteria® rectal cancer. ONCOLOGY (United States). 28.
    49. What is the Significance of Indeterminate Pulmonary Nodules in Patients Undergoing Resection for Pancreatic Adenocarcinoma?. Journal of Gastrointestinal Surgery. 19:841-847.
    50. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecologic Oncology.
    51. Primary Pancreatic Adenocarcinoma. 526-533.
    52. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. JNCCN Journal of the National Comprehensive Cancer Network. 13:1225-1231.
    53. Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma. Annals of Surgical Oncology. 22:1100-1106.
    54. Locally advanced, unresectable pancreatic cancer. Journal of Clinical Oncology. 34:2654-2667.
    55. Predictors of improved survival for patients with retroperitoneal sarcoma. Surgery (United States). 160:1628-1635.
    56. Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. JAMA Surgery. 148:1095-1102.
    Same Department Expand Description